Key facts
- MultivisionDx’s last known valuation is $5.2M (Dec 2025).
- It has raised $1.2M; the latest was Seed Round ($1.2M) in Dec 2025.
- Notable investors include Antler, Health Incubator Helsinki, Kaikarhenni, University of Helsinki, Y Science.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for MultivisionDx
- ·The full record, as it builds
Funding rounds
No funding rounds for MultivisionDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MultivisionDx
Provider of AI-powered decision-support tools intended for personalized cancer diagnosis and treatment selection. The company generates patient-specific tumor profiles, enabling clinicians to assess tumor aggressiveness and tailor effective treatment strategies for individual patients.
- Sector
- Healthcare
- HQ
- Helsinki, Finland
- Website
- multivision.ai/
- Ownership
- Privately Held (backing)
MultivisionDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MultivisionDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MultivisionDx in its N-PORT filings yet. We sweep new filings monthly.